EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cullinan Therapeutics's enterprise value is $800.07 Mil.
Cullinan Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Cullinan Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for Cullinan Therapeutics's EV-to-Revenue or its related term are showing as below:
During the past 6 years, the highest EV-to-Revenue of Cullinan Therapeutics was 68.28. The lowest was 2.90. And the median was 13.48.
CGEM's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.14 * Ranked among companies with meaningful EV-to-Revenue only.
Cullinan Therapeutics EV-to-Revenue Historical Data
The historical data trend for Cullinan Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cullinan Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Cullinan Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cullinan Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cullinan Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Cullinan Therapeutics's EV-to-Revenue falls into.
Cullinan Therapeutics's current Enterprise Value is $800.07 Mil.
Cullinan Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cullinan Therapeutics's share price for today is $28.79.
Cullinan Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cullinan Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Cullinan Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Cullinan Therapeutics (Cullinan Therapeutics) Business Description
Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CGEM has been successfully added to your 